Orexigen Therapeutics, Inc.
Overview
Orexigen Therapeutics, Inc. was a biopharmaceutical company focused on developing pharmaceutical products for the treatment of obesity. The company's main product was Contrave, a combination drug that was intended to help patients with weight management. Orexigen faced financial challenges and eventually entered bankruptcy proceedings.
Therapeutic areas
FDA compliance signals
2 FDA enforcement records linked to this company.
- recall — Class III2018-11-14
Container packaging defect.
- recall — Class III2018-08-22
Defective Container: Customer complaints of punctures in the bottle.
Is this Orexigen Therapeutics, Inc.? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.